Comparative evaluation of PRRS virus infection in vaccinated and naïve pigs

Res Vet Sci. 2011 Apr;90(2):218-25. doi: 10.1016/j.rvsc.2010.06.011. Epub 2010 Jul 2.

Abstract

The purpose of this study was to evaluate the time-course of the immune response to a field Porcine Respiratory and Reproductive Syndrome virus (PRRSV) strain in PRRS-naïve, untreated pigs, as well as in four groups of age and breed-matched pigs injected with a live attenuated PRRS vaccine, its adjuvant, an inactivated PRRS vaccine and an irrelevant, inactivated Porcine Circovirus type 2 (PCV2) vaccine, respectively. PRRSV infection was confirmed in all groups by PCR and antibody assays. The antibody response measured by ELISA took place earlier in pigs injected with the live attenuated vaccine, which also developed a much stronger serum-neutralizing antibody response to the vaccine strain. Yet, no clear protection was evidenced in terms of viremia against the field virus strain, which showed 11.1% nucleotide divergence in ORF7 from the vaccine strain. In vitro, the interferon (IFN)-γ response to PRRSV was almost absent on PVD 60 in all groups under study, whereas the prevalence of interleukin (IL)-10 responses to PRRSV was fairly high in PCV2-vaccinated animals, only. Results indicate that distinct patterns of immune response to a field PRRSV strain can be recognized in PRRS-vaccinated and naïve pigs, which probably underlies fundamental differences in the development and differentiation of PRRSV-specific immune effector cells.

MeSH terms

  • Animals
  • Antibodies, Neutralizing
  • Cells, Cultured
  • Cytokines / metabolism
  • Enzyme-Linked Immunosorbent Assay / veterinary
  • Gene Expression Regulation / immunology
  • Immunity, Cellular
  • Immunoglobulin G / blood
  • Leukocytes / metabolism
  • Porcine Reproductive and Respiratory Syndrome / immunology
  • Porcine Reproductive and Respiratory Syndrome / prevention & control*
  • Swine
  • Viral Vaccines / immunology*
  • Viremia

Substances

  • Antibodies, Neutralizing
  • Cytokines
  • Immunoglobulin G
  • Viral Vaccines